[1] BOZZENA WZ, URSZULA R, GRZEGORZ J, et al. Anti-hepatitis C virus seroprevalence in the working age population in Poland, 2004 to 2014[J]. Euro Surveill, 2017, 22(2): 30441.
[2] ARNOLFO P, SAMANTHA M, GIOVANNA L, et al. Global epidemiology of hepatitis C virus infection An up-date of the distribution and circulation of hepatitis C virus genotypes[J]. World J Gastroenterol, 2016, 22(34): 7824. doi: 10.3748/wjg.v22.i34.7824
[3] BOGNAŚK, EWELINA K, EWA S, et al. Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C[J]. World J Gastroenterol, 2017, 23(21): 3815. doi: 10.3748/wjg.v23.i21.3815
[4] MOHD HANAFIAH K, GROEGER J, FLAXMAN AD, et al. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence[J]. Hepatology, 2013, 57(4): 1333. doi: 10.1002/hep.26141
[5] CHEN Y, YU CS, YIN XR, et al. Hepatitis C virus genotypes and subtypes circulating in mainland China emerg microbes infect[J]. Emerging Microbes Infections, 2017, 6(11): e95.
[6] LI MY, ZHUANG H, WEI L. How would China achieve WHO's target of eliminating HCV by 2030?[J]. Expert Rev Anti Infect Ther, 2019, 17(10): 763. doi: 10.1080/14787210.2019.1675509
[7] QIN Q, SMITH MK, WANG L, et al. Hepatitis c virus infection in china: An emerging public health issue[J]. J Viral Hepat, 2015, 22(3): 238. doi: 10.1111/jvh.12295
[8] CICIOǦLU AB, AYNALI A, KAYA S, et al. Comparison of HCV core antigen and anti-HCV with HCV RNA results[J]. Afr Health Sci, 2014, 14(4): 816.
[9] ZAMEER M, JESSIE M, YUSUKE S, et al. Clinical utility of HCV core antigen detection and quantification using serum samples and dried blood spots in people who inject drugs in Dar-es-Salaam, Tanzania[J]. J Int AIDS Soc, 2017, 20(1): 21856. doi: 10.7448/IAS.20.1.21856
[10] YUE ZH, XIA CS, WANG H. Performance evaluation of the mindray anti-HCV assay for the detection of hepatitis C virus infection[J]. J Clin Lab Anal, 2018, 32(9): e22600.
[11] FLAMM SL. Chronic hepatitis C virus infection[J]. JAMA, 2003, 289(18): 2413. doi: 10.1001/jama.289.18.2413
[12] GALLI C, JULICHER P, PLEBANI M. HCV core antigen comes of age: a new opportunity for the diagnosis of hepatitis C virus infection[J]. Clin Chem Lab Med, 2018, 56(6): 880. doi: 10.1515/cclm-2017-0754
[13] LAPERCHE S, NUBLING CM, STRAMER SL, et al. Sensitivity of hepatitis C virus core antigen and antibody combination assays in a global panel of window period samples[J]. Transfusion, 2015, 55(10): 2489. doi: 10.1111/trf.13179
[14] ALONSO R, PÉÍREZ-GARCÍA F, AMPUERO D, et al. New direct-acting antivirals for patients with chronic HCV infection: can we monitor treatment using an HCV core antigen assay?[J]. Diagn Microbiol Infect Dis, 2017, 87(3): 243. doi: 10.1016/j.diagmicrobio.2016.11.010
[15] ALONSO R, PÉREZ-GARCÍA F, LÍPEZ-ROA P, et al. HCV core-antigen assay as an alternative to HCV RNA quantification: A correlation study for the assessment of HCV viremia[J]. Enferm Infecc Microbiol Clin, 2018, 36(3): 175. doi: 10.1016/j.eimc.2016.11.013
[16] ÇETINER S, ÇETIN DURAN A, KIBAR F, et al. Performance comparison of new generation HCV core antigen test versus HCV RNA test in management of hepatitis C virus infection[J]. Transfus Apher Sci, 2017, 56(3): 362. doi: 10.1016/j.transci.2017.02.005
[17] RUJIPAT W, PREEYAPORN V, CHOMPOONUT A, et al. HCV core antigen is an alternative marker to HCV RNA for evaluating active HCV infection implications for improved diagnostic option in an era of affordable DAAs[J]. Peer J, 2017, 5: e4008. doi: 10.7717/peerj.4008
[18] YANG N, LI ZR, YAN M, et al. Evaluation of Serum Alpha-Fetoprotein Level in Chronic Hepatitis C Patients[J]. Clin Lab, 2019, 65(1): 16.
[19] SAMIRA B, FAEZEH S, SANAZ AG, et al. Prediction of HCV load using genotype, liver biomarkers, and clinical symptoms by a mathematical model in patients with HCV infection[J]. Microbiol Immunol, 2019, 63(11): 449. doi: 10.1111/1348-0421.12735